Stiripentol (N03AX17)

TENDER DESCRIPTION

The Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the aim of concluding rebate agreements pursuant to Section 130a(8) of SGB V with all suitable pharmaceutical companies for the active ingredient stated under BT-21-Lot (ATC) and, if applicable, with restrictions to certain dosage forms within the framework of a so-called “Open-House procedure”. Under the requirement of uniform contractual terms and a uniform access procedure, the conclusion or accession to a rebate agreement pursuant to Section 130a(8) of SGB V for the aforementioned active ingredient is offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. Interested pharmaceutical companies may request the participation documents and the contract from the contact address stated. A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents in full, duly completed and signed. A contract is concluded with each pharmaceutical company that meets the participation requirements. No exclusivity is provided. Accession and/or conclusion of the contract may take place at any time under…

TENDER BRIEF

TENDER DOCUMENTS